About Us

Navier Medical specialises in the development and commercialisation of medical image analysis solutions to reduce the impact of cardiovascular disease and improve patient health outcomes

The journey so far

Preloader

  • 2013

    The Vascular Engineering Lab (VascLab) is established by A/Prof Barry Doyle, a biomedical engineer at UWA, with a focus on using engineering to better understand heart disease.

  • 2014

    Barry collaborates with Prof Carl Schultz, a cardiologist at UWA and the Royal Perth Hospital, on coronary artery disease. Lachlan Kelsey begins his PhD on the project.

  • 2016

    VascLab moves to the Harry Perkins Institute of Medical Research and the lab’s focus on medical devices to treat heart disease begins to accelerate.

  • 2018

    Project results are encouraging and efforts begin to commercialize the technology, with help from Dr Sam South at UWA.

  • 2019

    Lachlan completes his PhD and UWA provides Barry with funding to explore commercialization. De-risking activities are performed with the product development company Planet Innovation.

  • 2020

    A voice of customer study is performed with Curve Tomorrow and further de-risking is performed through ANDHealth workshops.

  • 2021

    Barry founds Navier Medical Limited and the company spins out of the university system. Otto Buttula takes a stake in the company, and Barry connects with Sander Bangma. Lachlan joins Navier Medical full-time and the company wins the WA Innovator of the Year Award in the Emerging Innovation category.

  • 2022

    Otto joins the company as Executive Chairman, Sander commences as CEO and Barry resigns from UWA and becomes CTO. Navier Medical is awarded the ‘Most Outstanding Patient Innovation’ by the Australian Patients Association.

  • 2023

    Navier moves into a new HQ and begins to build its culture while also progressing with technical development and marketing approvals of its first product, Mosaic.

The journey so far

Preloader

  • 2013

    The Vascular Engineering Lab (VascLab) is established by A/Prof Barry Doyle, a biomedical engineer at UWA, with a focus on using engineering to better understand heart disease.

  • 2014

    Barry collaborates with Prof Carl Schultz, a cardiologist at UWA and the Royal Perth Hospital, on coronary artery disease. Lachlan Kelsey begins his PhD on the project.

  • 2016

    VascLab moves to the Harry Perkins Institute of Medical Research and the lab’s focus on medical devices to treat heart disease begins to accelerate.

  • 2018

    Project results are encouraging and efforts begin to commercialize the technology, with help from Dr Sam South at UWA.

  • 2019

    Lachlan completes his PhD and UWA provides Barry with funding to explore commercialization. De-risking activities are performed with the product development company Planet Innovation.

  • 2020

    A voice of customer study is performed with Curve Tomorrow and further de-risking is performed through ANDHealth workshops.

  • 2021

    Barry founds Navier Medical Limited and the company spins out of the university system. Otto Buttula takes a stake in the company, and Barry connects with Sander Bangma. Lachlan joins Navier Medical full-time and the company wins the WA Innovator of the Year Award in the Emerging Innovation category.

  • 2022

    Otto joins the company as Executive Chairman, Sander commences as CEO and Barry resigns from UWA and becomes CTO. Navier Medical is awarded the ‘Most Outstanding Patient Innovation’ by the Australian Patients Association.

  • 2023

    Navier moves into a new HQ and begins to build its culture while also progressing with technical development and marketing approvals of its first product, Mosaic.

Team

Otto Buttula

Executive Chairman

  • Extensive experience and success in investment, funds management and Info/Bio-Tech.
  • Built and grew IWL Ltd (ASX: IWL) prior to takeover by CommBank (ASX: CBA).
  • Director/Chair in several ASX listed companies including HUB24 Ltd (ASX: HUB),
  • Imugene Ltd (ASX: IMU), Rhythm Biosciences (ASX: RHY), HitIQ (ASX: HIQ) and Oncosil Ltd (ASX: OSL).

A/Prof Barry Doyle

Founder & Executive Director

  • Ex-Program Head of Cardiovascular Science & Head of the Vascular Engineering Lab at the Harry Perkins Institute of Medical Research.
  • Adj. A/Professor of Biomedical Engineering at UWA with over 16 years experience in cardiovascular biomechanics.
  • BEng, PhD, FIEAust, GAICD.

Sander Bangma

Managing Director & CEO

  • Over 12 yrs experience in SaMD, including obtaining FDA, TGA & CE clearances.
  • Led ASX listed SaMD company Resonance Health Ltd (ASX:RHT) as GM & COO from 2015 to end 2017.
  • Significant experience leading large-scale global platform strategy & development (Moodle, 300m+ users).
  • MBA, MSc in CompSci.

Dr Lachlan Kelsey

Head of Engineering

  • Significant industry experience in computational mechanics.
  • Co-developed methods behind the Navier Medical during his PhD at the UWA.
  • PhD in Cardiovascular Biomechanics and BEng (Hons) in Mechanical Engineering.

Bronte Maddock

Quality Assurance and Regulatory Affairs Manager

  • Experienced compliance, regulatory affairs & risk management professional.
  • Comprehensive understanding of Medical Device ISO standards & regulations, including FDA, TGA and EU.

Tom Churack

Software Engineer

  • Experienced Software Engineer with a strong background in regulated, safety-critical and distributed software solutions.
  • BEng in Electrical and Electronic Engineering and BCM in Computer and Mathematical Sciences.